查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994246

化疗诱发週边神经神经病变治疗市场：2026年至2032年全球市场预测（依治疗方法、给药途径、患者年龄层、治疗时间和最终用户划分）

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Therapy Duration, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，化疗引起的周边神经病变治疗市场价值将达到 10.5 亿美元，到 2026 年将成长到 11.3 亿美元，到 2032 年将达到 18.8 亿美元，复合年增长率为 8.64%。

主要市场统计数据
基准年 2025 10.5亿美元
预计年份：2026年 11.3亿美元
预测年份 2032 18.8亿美元
复合年增长率 (%) 8.64%

权威总结了影响肿瘤学各个领域中 CIPN（化疗引起的周围神经病变）管理的不断变化的临床重点、护理路径和相关人员压力。

化疗引起的周边神经病变（CIPN）仍然是一个持续存在的临床挑战，它不仅影响患者的生活质量，也增加了肿瘤治疗路径的复杂性。随着肿瘤治疗方法的多样化和生存期的延长，临床医生越来越重视在维持抗癌疗效的同时减轻神经病变症状的干预措施。这种不断变化的临床需求促使人们关注兼顾药物治疗、非药物治疗和支持性治疗的多方面综合管理方法。

临床实践、创新和关键变革的轨迹正在重塑支付方对 CIPN 护理的期望。

近年来，持续性重症监护计画（CIPN）领域受到多项协同变化的影响，这些变化改变了治疗方法的评估、应用和报销方式。首先，人们越来越重视以病人为中心的终点指标和功能性结局，这使得非药物疗法与传统药物疗法并存的接受度不断提高。其次，神经生物学和生物标记发现的进步使得预防和缓解症状的方法更具针对性，并能够进行基于风险和机制对受试者进行分层的临床试验。第三，在支付方框架内，对可证实的临床效益和整合到治疗路径中的需求日益增长，这迫使研发人员设计出超越随机对照试验的证据包。

对 2025 年美国关税措施对供应链、准入和临床营运的累积影响进行预测分析。

美国关税的潜在变化可能会对整个化疗诱发週边神经病变（CIPN）治疗生态系统产生连锁反应，改变供应链成本、筹资策略策略和製造地地点。提高药品活性成分、医疗设备或组件的进口关税可能会促使製造商和经销商重新评估其采购、库存策略和供应商多元化。因此，医疗机构和专科诊所可能面临采购计划和单位成本的变化，这可能会影响药物选择和医疗设备部署计划。因此，越来越需要製定供应链韧性规划，包括关键投入品的地理多元化以及提高对上游生产风险的可见性。

主导细分市场洞察，揭示治疗方法选择模式、首选给药方法、人口统计优先事项、治疗持续时间考量和医疗保健服务环境。

化疗诱导週边神经病变 (CIPN) 的治疗方案取决于多种治疗方法及其应用的临床背景。根据治疗类型，相关人员会将药物治疗（例如抗惊厥药、抗忧郁症和鸦片类药物）与非药物疗法（例如针灸、物理治疗和经皮神经电刺激 (TENS)）进行比较。这种权衡反映了疗效、耐受性以及尽量减少对癌症治疗干扰的必要性。给药途径也会影响临床决策。口服製剂常用于控制慢性症状，而当需要全身控制时，则采用包括肌肉注射和静脉注射在内的肠外给药疗法；此外，还有具有局部缓解作用且安全性良好的外用製剂可供选择。

区域观点着重分析医疗基础设施、政策驱动因素以及与 CIPN 管理相关的创新采用模式的差异。

地理环境对化疗诱导週边神经病变 (CIPN) 的管理至关重要，因为不同地区的法规环境、报销机制和医疗基础设施存在差异。在美洲，成熟的肿瘤网络、活跃的临床研究以及支付方以结果为导向的策略，都支持将基于指南的治疗方法与医疗设备和数位健康解决方案相结合。而在其他地区，不断变化的报销模式和获得专科医疗服务的机会差异，影响着治疗方案的部署模式，因此需要製定切实可行且经济高效的干预措施，以便在不同的医疗环境中实施。

企业级策略洞察，重点在于塑造 CIPN 解决方案的竞争定位、合作趋势和创新重点领域。

在CIPN（压迫性细胞内疼痛和神经性疼痛）领域营运的公司正采取多种策略来巩固其市场地位，包括产品组合多元化、临床合作以及技术驱动的服务模式。成熟的製药公司通常专注于拓展适应症、优化配方或支持疗效比较研究，以在神经性疼痛治疗​​指南中区分已知药物。同时，专业的医疗设备开发商和数位医疗公司则优先考虑易用性、远端监测以及在真实临床环境中验证功能性益处的证据。随着各公司寻求以经济高效的方式生产并快速交付外用製剂和医疗设备耗材给医疗专业人员，契约製造和供应合作伙伴的重要性日益凸显。

为临床领导者、开发人员和商业负责人提供实用建议，以加速CIPN护理的采用并改善患者的治疗效果。

优先考虑与真实临床需求相符的证据，设计包含患者报告结局、功能评估指标以及保险公司和临床医生认为具有说服力的可操作终点的研究。同时，投资于整合式医疗模式，将药物治疗、非药物治疗和数位症状监测相结合，以支持门诊和居家环境中的持续照护。制定关键原料的多元化筹资策略，与本地製造合作伙伴合作以缩短前置作业时间，并减轻贸易中断的影响，从而降低供应链和政策风险。

一份透明的调查方法概要，解释瞭如何整合、检验和组合证据以支持实际见解。

本研究采用的方法结合了对同侪审查的临床文献、监管指南和公开的临床试验註册资讯的系统性回顾，以及对临床专家、供应链专家和医疗政策相关人员的结构化访谈。在整合证据时，我们优先考虑高品质的随机对照试验、Meta分析和指南建议，并用真实世界数据和观察性研究来补充任何不足之处，这些数据和研究突出了实施过程中遇到的挑战。专家咨询提供了不同医疗机构中临床实践的实际情况、实施障碍和未满足需求的背景性解释。

总结整合工作，强调了采取综合方法来改善患者疗效的紧迫性，同时克服了商业性和政策方面的阻力。

化疗诱导週边神经病变 (CIPN) 的挑战涉及生物学、症状管理和医疗保健系统设计等多个方面。有效的因应措施需要整合策略，结合可靠的临床证据、高度灵活的照护模式和稳健的供应链。随着临床重点转向以病人为中心的疗效和功能维持，相关人员必须协调研发、报销和实施计划，以在日常实践中展现显着疗效。同样重要的是，製药公司、医疗设备开发商、临床医生和保险公司之间需要持续合作，才能将机制研究的进展转化为可在所有医疗机构实施的可操作干预措施。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：化疗诱发週边神经神经病变（依治疗方法划分）

  • 非药物治疗
    • 针刺
    • 物理治疗
    • 经皮电神经刺激
  • 药物治疗
    • 抗惊厥药物
    • 抗忧郁症
    • 阿片类药物

第九章：化疗诱发週边神经病变治疗市场：依给药途径划分

  • 口服
  • 肠外
    • 肌肉内部
    • 静脉
  • 外用

第十章：依病患年龄组别分類的化疗诱发週边神经病变治疗市场

  • 成人
  • 老年人
  • 儿童

第十一章：化疗引起的周边神经病变（依治疗持续时间划分）

  • 长期治疗
  • 短期治疗

第十二章：化疗诱发週边神经病变治疗市场：依最终使用者划分

  • 居家医疗
  • 医院
  • 专科诊所

第十三章：化疗诱发週边神经病变治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：化疗诱发週边神经病变治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：化疗诱发週边神经病变治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国化疗诱发週边神经神经病变治疗市场

第十七章：中国化疗诱发週边神经神经病变治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AlgoTherapeutix
  • Amgen Inc.
  • Array BioPharma Inc. by Pfizer Inc.
  • Artelo Biosciences, Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bexion Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Grunenthal GmbH
  • Heron Therapeutics, Inc.
  • Ipsen Pharma
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Neuralace Medical
  • Novartis AG
  • Regenacy Pharmaceuticals LLC
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Serpin Pharma, LLC
  • Takeda Pharmaceutical Company Limited
  • Veloxis Pharmaceuticals, Inc.
Product Code: MRR-1A1A064C04DA

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.13 billion in 2026, with a CAGR of 8.64%, reaching USD 1.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.05 billion
Estimated Year [2026] USD 1.13 billion
Forecast Year [2032] USD 1.88 billion
CAGR (%) 8.64%

An authoritative synopsis of the evolving clinical priorities, care pathways, and stakeholder pressures shaping CIPN management across oncology settings

Chemotherapy-induced peripheral neuropathy (CIPN) remains a persistent clinical challenge that affects patient quality of life and can complicate oncology care pathways. As oncology regimens diversify and survivorship grows, clinicians increasingly prioritize interventions that reduce neuropathic symptoms while preserving anticancer efficacy. This evolving clinical imperative has elevated interest in multimodal management approaches that balance pharmacological therapy with non-pharmacological interventions and supportive care strategies.

Consequently, payers, health systems, and specialty clinics are aligning protocols to emphasize symptom relief, functional preservation, and continuity of cancer therapy. These stakeholders are also contending with constrained resources and competing priorities, which makes evidence-backed, cost-effective interventions especially attractive. In parallel, research communities are broadening the investigative lens to include preventive strategies, mechanistic biomarkers, and patient-reported outcome measures that better capture the lived experience of CIPN.

Taken together, the current landscape demands integrated thinking across clinical development, service delivery, and commercial strategy. By focusing on multidisciplinary solutions that are adaptable across care settings, stakeholders can better address unmet needs while managing complexity across regulatory, reimbursement, and supply chain dimensions.

Key transformative shifts reshaping clinical practice, innovation trajectories, and payer expectations in CIPN care

Over recent years the CIPN landscape has been reshaped by several converging shifts that alter how therapies are evaluated, adopted, and reimbursed. First, there is stronger emphasis on patient-centered endpoints and functional outcomes, which has expanded acceptance of non-pharmacological modalities alongside traditional drug therapies. Second, advances in neurobiology and biomarker discovery are informing more targeted approaches to prevention and symptomatic relief, enabling trials that stratify participants by risk and mechanism. Third, payer frameworks are increasingly demanding demonstrable real-world benefit and care pathway integration, prompting developers to design evidence packages that extend beyond randomized controlled trials.

Moreover, digital health tools and remote monitoring technologies have accelerated integration of home-based assessments, facilitating continuous symptom tracking and adaptive management. Meanwhile, growing scrutiny of opioid-based strategies has encouraged diversification toward anticonvulsants, antidepressant agents used for neuropathic pain, topical formulations, and device-based therapies. These combined forces are incentivizing cross-disciplinary partnerships among drug developers, device manufacturers, clinical networks, and health technology vendors, driving a more collaborative innovation model that emphasizes pragmatic, scalable solutions.

Analysis of the projected cumulative effects of prospective United States tariff measures on supply chains, access, and clinical operations in 2025

Potential tariff changes in the United States can reverberate through the CIPN therapy ecosystem by altering supply chain costs, procurement strategies, and manufacturing footprints. An increase in import duties on active pharmaceutical ingredients, medical devices, or component materials would likely prompt manufacturers and distributors to reassess sourcing, inventory strategies, and supplier diversification. In turn, providers and specialty clinics may experience changes in procurement timelines and unit costs that influence formulary decisions and device deployment plans. Consequently, there is a heightened need for supply chain resilience planning that includes geographic diversification of key inputs and greater visibility into upstream manufacturing risks.

At the clinical level, administrative burdens associated with altered customs processes and longer lead times could affect timely availability of topical agents, patches, and device consumables used in outpatient and home care settings. In addition, tariff-driven cost pressures may accelerate shifts toward generics, local manufacturing partnerships, or vertically integrated supply arrangements. From a strategic perspective, stakeholders should evaluate the interplay between trade policy, regulatory approvals, and domestic manufacturing incentives to preserve continuity of care and to mitigate unintended barriers to patient access.

Segmentation-driven insights that illuminate treatment choices, administration preferences, demographic priorities, duration considerations, and care delivery settings

Treatment selection for CIPN is shaped by a spectrum of therapeutic modalities and the clinical contexts in which they are deployed. Based on treatment type, stakeholders weigh pharmacological options such as anticonvulsants, antidepressants, and opioids against non-pharmacological alternatives that include acupuncture, physical therapy, and transcutaneous electrical nerve stimulation; this balancing act reflects efficacy evidence, tolerability, and the need to minimize interference with cancer therapy. Route of administration considerations also influence clinical decision-making, with oral agents frequently used for chronic symptom management, parenteral options employed when systemic control is required including intramuscular and intravenous approaches, and topical formulations offering localized relief with favorable safety profiles.

Patient age group is a critical filter for therapy design and delivery, as adults, geriatric patients, and pediatric populations present distinct risk-benefit profiles, comorbidity burdens, and adherence challenges. Therapy duration further influences care plans, where short-term interventions target acute or transient neuropathic episodes and long-term therapy prioritizes sustained symptomatic control and functional preservation. End-user environments shape implementation feasibility and resource allocation; home care settings favor user-friendly, low-burden interventions that support self-management, hospitals must integrate CIPN protocols into complex oncology workflows, and specialty clinics often deliver multimodal, multidisciplinary care with access to device-based therapies and procedural options.

Understanding these intersecting segmentation dimensions enables more precise pathway design, targeted evidence generation, and tailored commercialization strategies that resonate with clinicians, caregivers, and patients across diverse clinical contexts.

Regional perspectives that highlight differing healthcare infrastructures, policy drivers, and innovation adoption patterns relevant to CIPN management

Geographic context matters deeply for CIPN management, as regions demonstrate distinct regulatory environments, reimbursement mechanisms, and care delivery infrastructures. In the Americas, established oncology networks, robust clinical research activity, and payer emphasis on outcomes have supported integration of guideline-based therapies alongside device and digital health solutions. Elsewhere, evolving reimbursement models and varied access to specialty services shape adoption patterns and demand pragmatic, cost-conscious interventions that can be delivered across diverse care settings.

Within Europe, Middle East & Africa, regulatory harmonization in some markets contrasts with fragmented procurement and variable specialist availability in others, making regionally tailored evidence and pricing strategies essential. In the Asia-Pacific region, rapid capacity expansion in oncology services, growing clinical trial activity, and increasing investment in domestic manufacturing create both opportunities and operational complexities for companies seeking regional scale. Across all regions, differences in clinician training, patient expectations, and health system priorities require adaptive commercialization and partnership approaches to ensure therapies reach appropriate patient populations while aligning with local standards of care.

Strategic company-level insights highlighting competitive positioning, partnership trends, and innovation focus areas shaping CIPN solutions

Companies active in the CIPN domain are pursuing multiple pathways to strengthen their market positions, including portfolio diversification, clinical collaboration, and technology-enabled service models. Established pharmaceutical manufacturers often focus on expanding label indications, optimizing delivery formulations, or supporting comparative effectiveness research to differentiate familiar agents within neuropathic pain guidelines. Specialized device developers and digital health firms emphasize usability, remote monitoring, and evidence generation that demonstrates functional benefits in real-world settings. Contract manufacturers and supply partners are increasingly important as firms seek cost-efficient production and faster time-to-provider for topical formulations and device consumables.

Across the ecosystem, strategic alliances and clinical partnerships are common as stakeholders combine therapeutic expertise with procedural skills and digital capabilities. Intellectual property strategies lean toward formulation patents, device innovations, and data-driven approaches to outcome measurement. Meanwhile, competitive pressures from generics and off-label prescribing drive a focus on value demonstration, patient stratification, and niche positioning that highlights safety, tolerability, and integration into multidisciplinary care pathways.

Actionable recommendations for clinical leaders, developers, and commercial strategists to accelerate adoption and improve patient outcomes in CIPN care

Prioritize evidence that aligns with real-world clinical needs by designing studies that incorporate patient-reported outcomes, functional measures, and pragmatic endpoints that payers and clinicians find compelling. Simultaneously, invest in integrated care models that combine pharmacological therapies with non-pharmacological modalities and digital symptom monitoring to support continuity of care in outpatient and home environments. To mitigate supply chain and policy risk, develop diversified sourcing strategies for critical inputs and engage with regional manufacturing partners to reduce lead times and exposure to trade disruptions.

Engage proactively with payer bodies and clinical guideline committees to ensure that dossiers reflect the full spectrum of clinical value, including safety, quality-of-life impact, and health system efficiencies. Forge interdisciplinary partnerships across oncology, neurology, rehabilitation, and palliative care to accelerate adoption of multimodal protocols and to foster clinician champions. Finally, tailor commercialization strategies to the nuances of regional markets and care settings, emphasizing scalable training programs, implementation support, and outcomes tracking that demonstrate sustained patient benefit.

Transparent research methodology summary describing how evidence was integrated, validated, and synthesized to support actionable insights

The research approach combined systematic review of peer-reviewed clinical literature, regulatory guidance, and publicly available clinical trial registries with structured interviews of clinical experts, supply chain specialists, and health policy stakeholders. Evidence synthesis prioritized high-quality randomized controlled trials, meta-analyses, and guideline recommendations while supplementing gaps with real-world evidence and observational studies that illuminate implementation challenges. Expert consultations provided contextual interpretation of clinical practice realities, adoption barriers, and unmet needs across different care settings.

Data validation included cross-referencing therapeutic mechanisms, administration routes, and standard-of-care practices against clinical guidelines and specialist input to ensure consistency. Where policy or trade scenarios were analyzed, publicly available regulatory notices and trade documentation were reviewed to ground implications in verifiable developments. Finally, insights were iteratively reviewed by multidisciplinary advisors to refine recommendations and to ensure the final narrative supports pragmatic decision-making for clinicians, developers, and commercial teams.

Concluding synthesis that underscores the urgency of integrated approaches to improving patient outcomes while navigating commercial and policy headwinds

CIPN presents a multifaceted challenge that spans biology, symptom management, and health system design. Effective responses require integrated strategies that combine robust clinical evidence, adaptable care models, and resilient supply chains. As clinical priorities shift toward patient-centered outcomes and functional preservation, stakeholders must align development, reimbursement, and implementation plans to demonstrate meaningful benefit in routine practice. Equally important is the sustained collaboration among drug developers, device innovators, clinicians, and payers to translate mechanistic advances into pragmatic interventions that are accessible across care settings.

In summary, the path forward is characterized by opportunity for stakeholders who can generate relevant evidence, design for real-world implementation, and build operational resilience in the face of policy and supply uncertainties. By embracing multidisciplinary approaches and regionally tailored strategies, organizations can make measurable improvements in symptom control, patient quality of life, and continuity of cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Type

  • 8.1. Non-Pharmacological Treatments
    • 8.1.1. Acupuncture
    • 8.1.2. Physical Therapy
    • 8.1.3. Transcutaneous Electrical Nerve Stimulation
  • 8.2. Pharmacological Treatments
    • 8.2.1. Anticonvulsants
    • 8.2.2. Antidepressants
    • 8.2.3. Opioids

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Route of Administration

  • 9.1. Oral
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
  • 9.3. Topical

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Therapy Duration

  • 11.1. Long-Term Therapy
  • 11.2. Short-Term Therapy

12. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by End-User

  • 12.1. Home Care Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Chemotherapy Induced Peripheral Neuropathy Treatment Market

17. China Chemotherapy Induced Peripheral Neuropathy Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AlgoTherapeutix
  • 18.7. Amgen Inc.
  • 18.8. Array BioPharma Inc. by Pfizer Inc.
  • 18.9. Artelo Biosciences, Inc.
  • 18.10. Asahi Kasei Corporation
  • 18.11. Astellas Pharma Inc.
  • 18.12. Bexion Pharmaceuticals, Inc.
  • 18.13. Bristol-Myers Squibb Company
  • 18.14. Eisai Inc.
  • 18.15. F. Hoffmann-La Roche Ltd
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Glenmark Pharmaceuticals Ltd.
  • 18.18. Grunenthal GmbH
  • 18.19. Heron Therapeutics, Inc.
  • 18.20. Ipsen Pharma
  • 18.21. Kyowa Kirin Co., Ltd.
  • 18.22. Merck & Co., Inc.
  • 18.23. Neuralace Medical
  • 18.24. Novartis AG
  • 18.25. Regenacy Pharmaceuticals LLC
  • 18.26. Regeneron Pharmaceuticals, Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Serpin Pharma, LLC
  • 18.29. Takeda Pharmaceutical Company Limited
  • 18.30. Veloxis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)